Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1. Characteristics of the 197 patients with diffuse large B-cell lymphoma (DLBCL)

From: Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy

Variate Number of patients [cases (%)]
Sex  
  Male 119 (60.4)
  Female 78 (39.6)
Age ⩾ 60 years 48 (24.4)
Ann Arbor stage  
  I 31 (15.7)
  II 49 (24.9)
  III 42 (21.3)
  IV 75 (38.1)
IPI  
  Low (0 or 1) 91 (46.2)
  Low/intermediate (2) 36 (18.3)
  High/intermediate (3) 15 (22.8)
  High (4 or 5) 25 (12.7)
Chemotherapy  
  R-CHOP-14 28 (14.2)
  R-CHOP-21 169 (85.8)
  1. IPI, International Prognostic Index; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP-14, R-CHOP regimen administered with a 14-day interval; R-CHOP-21, R-CHOP regimen administered with a 21-day interval
Back to article page